UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act Of 1934

Date of report (Date of earliest event reported): November 27, 2016

 

 

ILLUMINA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-35406		33-0804655
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

		5200 Illumina Way, San Diego, CA				92122
		(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (858) 202-4500

 

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 27, 2016, Tristan Orpin, Executive Vice President, Clinical Genomics, notified Illumina, Inc. that he would be leaving the company in January 2017. Illumina has identified and agreed to employment terms with a successor to Mr. Orpin, who will join the company in January 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 29, 2016